Neus Bosch-Martinez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity.

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity.

Journal: Science advances
Published: May 08, 2026

Lateral flow immunoassay detection of soluble AXL for pancreatic ductal adenocarcinoma diagnosis.

Lateral flow immunoassay detection of soluble AXL for pancreatic ductal adenocarcinoma diagnosis.

Journal: Talanta
Published: April 10, 2026

Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells.

Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 02, 2025

Quantitative characterization of the 3D self-organization of PDAC tumor spheroids reveals cell type and matrix dependence through advanced microscopy analysis.

Quantitative characterization of the 3D self-organization of PDAC tumor spheroids reveals cell type and matrix dependence through advanced microscopy analysis.

Journal: APL bioengineering
Published: October 04, 2024

Validation of ZIP4 as a tumour-associated antigen for nanotargeting.

Validation of ZIP4 as a tumour-associated antigen for nanotargeting.

Journal: Journal of drug targeting
Published: September 16, 2024

Hallmarks of pancreatic cancer: spotlight on TAM receptors.

Hallmarks of pancreatic cancer: spotlight on TAM receptors.

Journal: EBioMedicine
Published: April 19, 2024

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment.

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 04, 2024

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.

Journal: Cells
Published: January 22, 2023

Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice.

Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice.

Journal: Cancers
Published: November 08, 2022

Exploring the Role of Galectins in Cancer : In Vitro and In Vivo Approaches.

Exploring the Role of Galectins in Cancer : In Vitro and In Vivo Approaches.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: March 23, 2022

Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells.

Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells.

Journal: Cancers
Published: January 24, 2022

Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.

Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.

Journal: EBioMedicine
Published: October 11, 2021
Showing 1-12 of 28

Last Updated: 09/26/2026